Sesen Bio Shares Gain On FDA Type A Meeting On Issues From Vicineum Response Letter

  • The FDA has granted Sesen Bio Inc's SESN request for a Type A meeting to discuss the Chemistry, Manufacturing, and Controls (CMC) issues raised in the Complete Response Letter for Vicineum for BCG-unresponsive non-muscle invasive bladder cancer.
  • Related: Sesen Bio Stock Crashes As FDA Shoots Down Its Bladder Cancer Pitch. 
  • The CMC Type A Meeting has been scheduled for October 29.
  • The Company is also preparing for a separate Type A meeting to discuss the recommendations specific to additional data and analyses raised in the CRL. 
  • The Company expects the Clinical Type A Meeting to happen later in Q4 of 2021. 
  • Also Read: Sesen Bio's Bladder Cancer Trial Wrecked By Misconduct: Stat News.
  • Related content: Benzinga's Full FDA Calendar.
  • Price Action: SESN shares are up 11.9% at $1.13 during the premarket session on the last check Wednesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsPenny StocksHealth CareFDAMoversTrading IdeasGeneralbladder cancerBriefswhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!